(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release
Posted in Business, Denmark, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharma, Board of Directors, CEO, Charl van Zyl, CNS, Deborah Dunsire, Eli Lilly, H. Lundbeck A/S, immunology, Lars Rasmussen, Lundbeck, Neurology, Novartis
(PRESS RELEASE) VALBY, Denmark, 22-Dec-2020 — /EuropaWire/ — Danish international pharmaceutical company, H. Lundbeck A/S (Lundbeck) announces that its marketing authorization application for Vyepti™ (eptinezumab-jjmr) has been accepted by the European Medicines Agency (EMA). The filing seeks approval to introduce … Read the full press release
Posted in Denmark, Healthcare, Marketing, News, Pharma & Biotech
Tagged calcitonin gene-related peptide, CGRP, Dr. Johan Luthman, EMA, eptinezumab-jjmr, European Medicines Agency, H. Lundbeck A/S, humanized monoclonal antibody, Juliane Lenzner, Lundbeck, marketing authorization, migraine, migraine preventive antibody, neurological disease, Palle Holm Olesen, preventative therapy, severe headaches, Vyepti™
Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults. VALBY, 01-Aug-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the European Commission has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia … Read the full press release
Posted in Denmark, Healthcare, Pharma & Biotech
Tagged brexpiprazole, European Commission, H. Lundbeck A/S, Ltd, Lundbeck, Otsuka, Otsuka Pharmaceutical Co., Rxulti, schizophrenia
Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018. VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a … Read the full press release
Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s … Read the full press release
Posted in Business, Denmark, Netherlands, Pharma & Biotech
Tagged acquisition, Anders Götzsche, dopaminergic, dyskinesia, Foliglurax, H. Lundbeck A/S, Parkinson's, Prexton Therapeutics BV, PTX002331
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
